Literature DB >> 26371421

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

Patrizia Pinciroli1, Helen Won2, Gopa Iyer3, Silvana Canevari4, Maurizio Colecchia5, Patrizia Giannatempo6, Daniele Raggi6, Marco A Pierotti7, Filippo G De Braud6, David B Solit8, Jonathan E Rosenberg3, Michael F Berger2, Andrea Necchi9.   

Abstract

Entities:  

Keywords:  Advanced disease; Angiogenesis; Clinical benefit; Next-generation sequencing; Pazopanib

Mesh：

Substances：

Year:  2015        PMID： 26371421      PMCID： PMC5003615          DOI： 10.1016/j.clgc.2015.07.017

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  13 in total

Review 1.  Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

Authors:  Guru Sonpavde; Cora N Sternberg; Jonathan E Rosenberg; Noah M Hahn; Matthew D Galsky; Nicholas J Vogelzang
Journal:  Lancet Oncol       Date:  2010-05-25       Impact factor: 41.316

2.  Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

Authors:  Guru Sonpavde; Gregory R Pond; Jonathan E Rosenberg; Dean F Bajorin; Ashley M Regazzi; Toni K Choueiri; Angela Q Qu; Guenter Niegisch; Peter Albers; Andrea Necchi; Giuseppe Di Lorenzo; Ronan Fougeray; Robert Dreicer; Yu-Hui Chen; Yu-Ning Wong; Srikala S Sridhar; Yoo-Joung Ko; Matthew I Milowsky; Matthew D Galsky; Joaquim Bellmunt
Journal:  Clin Genitourin Cancer       Date:  2014-10-02       Impact factor: 2.872

3.  Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.

Authors:  Norma Palma; John C Morris; Siraj M Ali; Jeffrey S Ross; Sumanta Kumar Pal
Journal:  Eur Urol       Date:  2015-03-09       Impact factor: 20.096

4.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

Authors:  Andrea Necchi; Luigi Mariani; Nadia Zaffaroni; Lawrence H Schwartz; Patrizia Giannatempo; Flavio Crippa; Carlo Morosi; Rodolfo Lanocita; Teodoro Sava; Cinzia Ortega; Caterina Messina; Cosimo Sacco; Marzia Pennati; Maria G Daidone; Nicola Nicolai; Filippo De Braud; Alessandro M Gianni; Roberto Salvioni
Journal:  Lancet Oncol       Date:  2012-07-20       Impact factor: 41.316

5.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

6.  Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Authors:  Christian D Young; Lisa J Zimmerman; Daisuke Hoshino; Luigi Formisano; Ariella B Hanker; Michael L Gatza; Meghan M Morrison; Preston D Moore; Corbin A Whitwell; Bhuvanesh Dave; Thomas Stricker; Neil E Bhola; Grace O Silva; Premal Patel; Dana M Brantley-Sieders; Maren Levin; Marina Horiates; Norma A Palma; Kai Wang; Philip J Stephens; Charles M Perou; Alissa M Weaver; Joyce A O'Shaughnessy; Jenny C Chang; Ben Ho Park; Daniel C Liebler; Rebecca S Cook; Carlos L Arteaga
Journal:  Mol Cell Proteomics       Date:  2015-05-07       Impact factor: 5.911

7.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Authors:  Eliezer M Van Allen; Kent W Mouw; Philip Kim; Gopa Iyer; Nikhil Wagle; Hikmat Al-Ahmadie; Cong Zhu; Irina Ostrovnaya; Gregory V Kryukov; Kevin W O'Connor; John Sfakianos; Ilana Garcia-Grossman; Jaegil Kim; Elizabeth A Guancial; Richard Bambury; Samira Bahl; Namrata Gupta; Deborah Farlow; Angela Qu; Sabina Signoretti; Justine A Barletta; Victor Reuter; Jesse Boehm; Michael Lawrence; Gad Getz; Philip Kantoff; Bernard H Bochner; Toni K Choueiri; Dean F Bajorin; David B Solit; Stacey Gabriel; Alan D'Andrea; Levi A Garraway; Jonathan E Rosenberg
Journal:  Cancer Discov       Date:  2014-08-05       Impact factor: 39.397

8.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Authors:  Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Eran Hodis; Susanna Jacobus; Jeffrey G Supko; Michelle Stewart; Toni K Choueiri; Leena Gandhi; James M Cleary; Aymen A Elfiky; Mary Ellen Taplin; Edward C Stack; Sabina Signoretti; Massimo Loda; Geoffrey I Shapiro; David M Sabatini; Eric S Lander; Stacey B Gabriel; Philip W Kantoff; Levi A Garraway; Jonathan E Rosenberg
Journal:  Cancer Discov       Date:  2014-03-13       Impact factor: 39.397

9.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

10.  Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.

Authors:  A Necchi; M Pennati; N Zaffaroni; E Landoni; P Giannatempo; D Raggi; L H Schwartz; C Morosi; F Crippa; E Farè; N Nicolai; R Lanocita; T Sava; C Sacco; C Messina; C Ortega; F G De Braud; R Salvioni; M G Daidone; A M Gianni; L Mariani
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640
View more
  1 in total

1.  CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Authors:  Thomas S Worst; Cleo-Aron Weis; Robert Stöhr; Simone Bertz; Markus Eckstein; Wolfgang Otto; Johannes Breyer; Arndt Hartmann; Christian Bolenz; Ralph M Wirtz; Philipp Erben
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.